Plain-English translation of NCT04969354 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of immunotherapy called CAR-T cell therapy, which uses your own immune cells that have been specially engineered in the lab to recognize and attack kidney cancer. Researchers will prepare your cells to target a specific protein called CAIX that appears on kidney cancer cells. The goal is to see if this personalized treatment can slow or stop the cancer's growth.
Many people with advanced kidney cancer stop responding to current standard treatments like targeted therapy or checkpoint inhibitor drugs. This trial exists to test whether this newer approach of using engineered immune cells might help patients whose cancers are no longer responding to these standard options.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. In the first phase, you would receive chemotherapy medications followed by an injection of an antibody into your liver, then receive an infusion of the engineered CAR-T cells plus supportive medications over about 4 weeks. Blood samples will be taken every 4 weeks to monitor how the cells are working. After an initial 6 months of close monitoring, you will have quarterly check-ups for 2 years, then annual phone check-ins for up to 5 years total to watch for long-term effects and cancer recurrence.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Collaborators
Xuzhou Medical University
Enrollment target
~20 participants
Started
October 2021
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in July 2021.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hailong Li, M.D/Ph.D
The Affiliated Hospital of Xuzhou Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.